Identification of catalase in human livers as a factor that enhances phenytoin dihydroxy metabolite formation by human liver microsomes

Biochemical Pharmacology

Volumn 63, Issue 12, 2002, Pages 2081-2090

  Komatsu, Tomoko ^a   Yamazaki, Hiroshi ^a   Nakajima, Miki ^a   Yokoi, Tsuyoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Catalase; Cytochrome P450; Cytosol; Enhancement; Human; Hydrogen peroxide; Liver; Microsomes; Phenytoin

Indexed keywords

AMMONIUM SULFATE; CATALASE; CELL PROTEIN; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DRUG METABOLITE; HYDROXYAPATITE; PHENYTOIN DIHYDROXY METABOLITE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CATALYSIS; COLUMN CHROMATOGRAPHY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG OXIDATION; ELECTROPHORESIS; ENZYME ACTIVITY; ENZYME PURIFICATION; HUMAN; HUMAN CELL; HYDROXYLATION; INCUBATION TIME; LIVER CYTOSOL; LIVER MICROSOME; MOLECULAR WEIGHT; PRECIPITATION; PRIORITY JOURNAL;

CATALASE; CYTOCHROME P-450 ENZYME SYSTEM; CYTOSOL; HUMANS; HYDROXYLATION; LIVER; MICROSOMES, LIVER; PHENYTOIN; RECOMBINANT PROTEINS;

EID: 0037098277     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01024-9     Document Type: Article

References (44)

1. Human cytochrome P450 enzymes
2. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
3. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
4. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy
5. Modulation of phenytoin teratogenicity and embryonic covalent binding by acetylsalicylic acid, caffeic acid, and α-phenyl-N-t-butylnitrone: Implications for bioactivation by prostaglandin synthetase
6. Phenytoin hypersensitivity: 38 cases
7. Pharmacokinetic drug interactions with phenytoin (part I)
8. Pharmacokinetic drug interactions with phenytoin (part II)
9. Ticlopidine-induced phenytoin toxicity
10. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite
11. Formation of a dihydroxy metabolite of phenytoin by human liver microsomes/cytosol: Roles of cytochrome P450 2C9, 2C19, and 3A4
12. Quantitative estimation of catechol/methylcatechol pathways in human phenytoin metabolism
13. Bioactivation of phenytoin by human cytochrome P450: Characterization of the mechanism and targets of covalent adduct formation
14. Requirement of a soluble protein for maximal activity of the mono-oxidase system of hepatic microsomes
15. Stabilization and induction of a lipid peroxidation inhibitor present in the soluble fraction of rat liver homogenates
16. Influence of microsomal and cytosolic fractions from the liver of 4 animal species and man on the mutagenicity of carcinogenic aminoazo dyes and nature of the mutagenicity-enhancing factor in the cytosol from rat liver
17. Influence of microsomal and cytosolic fractions from rat, mouse, and hamster liver on the mutagenicity of dimethylnitrosamine in the Salmonella plate incorporation assay
18. Bioactivation of N-nitrosopiperidine to mutagens: Role of hepatic cytochrome P-450 proteins and contribution of cytosolic fraction
19. The effect of cytosol on liver microsomal metabolic activation and demethylation of N-nitrosodimethylamine
20. Analysis and characterization of enzymes
21. Purification of functional recombinant P450s from bacteria
22. Immunological comparison of rat, rabbit, and human liver NADPH-cytochrome P-450 reductase
23. 5
24. 5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli
25. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature
26. Protein measurement with the Folin phenol reagent
27. Decreases in phenytoin hydroxylation activities catalyzed by liver microsomal cytochrome P450 enzymes in phenytoin-administered rats
28. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
29. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
30. Catalase in vitro
31. Irreversible reaction of 3-amino-1:2:4-triazole and related inhibitors with the protein of catalase
32. Inactivation of catalase by phenylhydrazine. Formation of a stable aryl-iron heme complex
33. A 7-hydroxymethyl sulfate ester as an active metabolite of 7,12-dimethylbenz[a]anthracene
34. Mutagenicity of 4-aminobiphenyl and 4-acetylaminobiphenyl in Salmonella typhimurium strains expressing different levels of N-acetyltransferase
35. Catalase: An old enzyme with a new role?
36. Understanding the structure and function of catalases: Clues from molecular evolution and in vitro mutagenesis
37. Maternal administration of superoxide dismutase and catalase in phenytoin teratogenicity
38. Superoxide dismutase, catalase and glutathione peroxidase activities in human blood: Influence of sex, age and cigarette smoking
39. Detection of a common mutation of the catalase gene in Japanese acatalasemic patients
40. Phenytoin-initiated DNA oxidation in murine embryo culture, and embryo protection by the antioxidative enzymes superoxide dismutase and catalase: Evidence for reactive oxygen species-mediated DNA oxidation in the molecular mechanism of phenytoin teratogenicity
41. Destruction of heme and hemoproteins mediated by liver microsomal reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase
42. Catalase in guinea pig hepatocytes is localized in cytoplasm, nuclear matrix and peroxisomes
43. Cytoplasmic and peroxisomal catalases of the guinea pig liver: Evidence for two distinct proteins
44. Purification and characterization of rat liver cytosol catalase